A new defect of peroxisomal function involving pristanic acid: a case report

B N McLean, J Allen, S Ferdinandusse, R J A Wanders

AN adult onset novel disorder of peroxisomal function is described, characterised by retinitis pigmentosa resulting in progressive visual failure, learning difficulties, a peripheral neuropathy, and hypogonadism. The defect results in accumulation of pristanic acid, and the bile acid intermediates, dihydroxycholestanolic and trihydroxycholestanolic acid, and is due to a deficiency of α-methylacyl-CoA racemase, making this the first fully characterised description of this defect. Screening of patients with retinitis pigmentosa should be extended to include pristanic acid and/or bile acid intermediate concentrations, as dietary measures offer a potential treatment for the disorder.

Peroxisomes are subcellular organelles found in all mammalian cell types, and are particularly abundant in cells specialising in lipid metabolism. Their main function is H₂O₂ metabolism, ether-phospholipid biosynthesis, β-oxidation of fatty acids and other compounds (very long chain fatty acids (VLCFAs)), monounsaturated and polyunsaturated fatty acids, prostaglandins, dihydroxycholestanolic acid/trihydroxycholestanolic acid (DHCA/THCA), xenobiotics), glyoxylate metabolism, polyamine catabolism, cholesterol and dolichol synthesis, and piperolic and phytanic acid degradation.²

Pristanic acid is derived from phytanic acid by α-oxidation, followed by decarboxylation, and also directly from exogenous dietary sources. Phytic acid is derived from purely exogenous sources, mainly dairy products and ruminant fats.³

Peroxisomes contain more than 60 enzymes so disorders of peroxisomal function result in several syndromes combining neurological and systemic features.⁴ Until 1999, 17 disorders had been described,⁵ 16 with neurological involvement.

The first well defined disorder described in 1946 was a hereditary ataxia, later to be given the eponym Refsum's disease,⁶ combining retinitis pigmentosa and a hypertrophic neuropathy associated with increased phytic acid. It was, however, only in 1997 that the true peroxisomal localisation of the disorder was confirmed, with the enzyme phytanoyl-α-methylacyl-CoA racemase (AMACR) making our patient one of the first adults to be described with this condition.⁷

CASE REPORT

A 44 year old man presented with failing vision, having been suspected by his general practitioner of malingering.

He was born of non-consanguineous parents, one of six children, his brother and four sisters being in good health. He had left school at the age of 14. He had been a poor scholar with reading difficulties and after leaving had a succession of unskilled jobs from which he was invariably dismissed. At the age of 18 he presented with an encephalitic illness characterised by 3 days of severe headache, nausea, and photophobia, with a single blackout followed by progressive confusion, irrational behaviour, and resulting in coma.

He developed focal seizures, with eye deviation to the left and jerking of the neck muscles, which on one occasion generalised. He had tonic deviation of his eyes to the right, sometimes with slow deviation, bilateral papilloedema, but no other focal neurological signs. He had a mild pyrexia and a neutrophilia, and an MRI showed gross disturbances consistent with multiple areas of hypointensity on the T2 scans. An EEG showed diffuse slowing.

He required ventilation, and then underwent spontaneous recovery, whereupon he was found to be blind. This was initially suspected to be due to occipital lobe infarction, but pigmentary retinal changes were seen extensively in the periphery of both fundi, and a neuroretinitis was proposed. His EEG improved, but did not return to normal, remaining slowed. Vision slowly recovered, initially with perception of light, then colours, and finally acuity of N24 right N18 left. A neuropsychometric assessment showed a premorbid verbal IQ of 86, a reading age of 7.5 years, and a long term problem with vision was suspected.

At the age of 22 he developed generalised seizures, only partially controlled with phenobarbital and phenytoin. An

In general, peroxisomal disorders present either at birth with deficits resulting in severe hypotonia and craniofacial dysmorphism or as later onset psychomotor retardation, seizures, and hepatomegaly. There is, however, a considerable range of clinical problems within a disorder and overlap between disorders, so that some can only be differentiated on biochemical grounds.

We present a case of adult onset neurological disease the features of which were reminiscent of a peroxisomal disorder, but in a novel combination.

The biochemical defect has been recently elucidated, and has been shown to be due to a deficiency of α-methylacyl-CoA racemase (AMACR) making our patient one of the first adults to be described with this condition.⁸

Abbreviations: VLCFA, very long chain fatty acids; DHCA/THCA, dihydroxycholestanolic/trihydroxycholestanolic acid; AMACR, α-methylacyl-CoA racemase

References:
EEG showed excessive slowing with a right temporal focus and a photoconvulsive response.

At the age of 25 he had an episode of status epilepticus, by which time his vision had declined to 6/36 right and 6/60 left uncorrected.

At the age of 34 he was involved in a road traffic accident and sustained a small right frontal extradural haematoma with confusion, not requiring surgery. After this he developed drop attacks and frequent headaches.

At the age of 41 he became aware of declining vision, and was found to have VA 1/18 L+R, constricted fields, and a generalised “retinopathy”.

When he presented at the age of 44, he was complaining of migrainous headaches daily from his accident, and a recent episode of amnesia with automatic behaviour. He had not been employed since his encephalopathy.

There was a family history of ischaemic heart disease, his father dying aged 67 of a heart attack. He was single without children, and taking only phenytoin and phenobarbital. There had been a previous episode of depression with an overdose, and he described a patient with Refsum’s disease who had an acute language skills. Encephalitic illnesses have not been noted as a longstanding premorbid problem with functional and language skills. Encephalitic illnesses have not been noted as a frequent or photoconvulsive response. Visually evoked potentials were abnormal bilaterally with low amplitude disrupted wave forms. Brain stem auditory evoked potentials were normal with N1-N5 latencies of 3.3 ms left, 3.96 ms right. Brain MRI showed minor cerebral atrophy only with normal white matter. Chest radiography was normal. Nerve conduction studies shows a peripheral symmetric sensory motor axonal neuropathy.

Table 1 lists the results of fatty acid and bile acid analyses in serum from the patient. The results show normal very long chain fatty acids, a slightly increased phytanic acid concentration, and profoundly increased pristanic acid concentration. Furthermore, both dihydroxycholestenoic acid and trihydroxycholestanoic acid are greatly increased.

These data pointed to a defect in the β-oxidation system which was supported by the finding of a reduced pristanic acid β-oxidation capacity (table 2). Subsequent studies showed that the primary defect in this patient was not at the level of the β-oxidation enzymes themselves but rather in one of the auxiliary enzymes involved in β-oxidation called α-methyl-acyl-CoA racemase.

DISCUSSION

Our patient had learning difficulties and his psychometric testing as an adult after his encephalitic illness suggested a longstanding premorbid problem with functional and language skills. Encephalitic illnesses have not been noted as a feature of peroxisomal disorders, although Goldman et al17 described a patient with Refsum’s disease who had an acute onset of ataxia after a viral illness—our patient was initially thought to have had a viral illness with pyrexia. Minor surgery may precipitate deterioration, so it could be postulated that oxidative stresses triggered decompensation or release of phytanic acid from fat stores as a result of catabolic stress. The oxidative stresses triggered decompensation or release of phytanic acid from fat stores as a result of catabolic stress. The association with encephalopathy we presume to be genuine, but coincidence cannot be excluded.

A comparison of his clinical features with those found in the other peroxisomal disorders shows a general similarity to those of late onset, particularly Refsum’s disease and in common with the single enzyme defects, if we have a seizure disorder with a peripheral neuropathy, no ataxia, a retinopathy and hypogonadism. His brain MRI did not show white matter abnormalities, as

### Table 1 Results of fatty acid and bile acid analysis from serum

<table>
<thead>
<tr>
<th>VCLFA profile</th>
<th>Value found</th>
<th>Normal</th>
</tr>
</thead>
<tbody>
<tr>
<td>C26 (µmol/l)</td>
<td>0.53</td>
<td>(0.03–1.39)</td>
</tr>
<tr>
<td>C26/C22</td>
<td>0.008</td>
<td>(&lt;0.030)</td>
</tr>
<tr>
<td>C24/C22</td>
<td>0.58</td>
<td>(0.32–0.92)</td>
</tr>
<tr>
<td>Phytanic acid (µmol/l)</td>
<td>20</td>
<td>(&lt;1.2)</td>
</tr>
<tr>
<td>Pristanic acid (µmol/l)</td>
<td>105</td>
<td>(&lt;3.0)</td>
</tr>
<tr>
<td>Pristanic/phytanic</td>
<td>5.25</td>
<td>(0.05–0.40)</td>
</tr>
<tr>
<td>Bile acid profile (µmol/l):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deoxycholic acid</td>
<td>0.02</td>
<td>(&lt;4.4)</td>
</tr>
<tr>
<td>Chenodeoxycholic acid</td>
<td>0.22</td>
<td>(0.22–12.4)</td>
</tr>
<tr>
<td>Cholic acid</td>
<td>0.44</td>
<td>(0.05–6.0)</td>
</tr>
<tr>
<td>Ursodeoxycholic acid</td>
<td>0.00</td>
<td>(&lt;2.1)</td>
</tr>
<tr>
<td>Hyocholic acid</td>
<td>0.00</td>
<td>(&lt;1.0)</td>
</tr>
<tr>
<td>Dihydroxycholestenoic acid</td>
<td>0.11</td>
<td>(not detectable)</td>
</tr>
<tr>
<td>Trihydroxycholestanoic acid</td>
<td>2.90</td>
<td>(not detectable)</td>
</tr>
<tr>
<td>Dihydroxycholestenoic acid</td>
<td>0.00</td>
<td>(not detectable)</td>
</tr>
<tr>
<td>C29 dicarboxylic acid</td>
<td>0.01</td>
<td>(not detectable)</td>
</tr>
</tbody>
</table>

### Table 2 Results from fibroblast studies

<table>
<thead>
<tr>
<th>Patient</th>
<th>De novo plasmalogen biosynthesis:</th>
<th>Normal</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DHAPAT activity</td>
<td>Normal</td>
</tr>
<tr>
<td></td>
<td>Pristanic acid β-oxidation activity*</td>
<td>284 ND</td>
</tr>
<tr>
<td></td>
<td>AMACR activity†</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Controls</th>
<th>Pristanic acid β-oxidation activity*</th>
<th>AMACR activity†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1147 (SD 325) [n=30]</td>
<td>92 (SD 30) [n=11]</td>
</tr>
</tbody>
</table>

ND, Not detectable. AMACR, α-methylacyl-CoA racemase.

For methods see Ferdinandusse16.
seen in adrenomyeloneuropathy, nor neuronal migration deficits as seen in a postmortem of infantile Refsum's disease. The biochemical defect causing Refsum's disease lies "upstream", yet the clinical phenotype of the disorders differ, although with considerable overlap. Why there should be this distinction is uncertain, but there may be a differential effect on tissues depending on the proportions of product accumulation (phytanic and pristanic acid and bile acid intermediates), or loss of lipid functions "downstream".

In humans, the only peroxisomal disorders of β-oxidation so far identified are those relating to VLCFAs, DHCA/THCA, and pristanic acid. Multiple enzymes are involved (fig 1) and abnormalities of pristanic acid metabolism were first associated with generalised peroxisomal disorders.

This currently described patient showed highly increased pristanic acid concentrations and mildly raised phytanic acid and VLCFA concentrations. Had the pristanic acid concentrations and mildly raised phytanic acid not been measured, the condition would have been missed, as peroxisomal disorders have always been assumed to cause abnormalities of VLCFA or phytanic acid.

The biochemical defect causing Refsum's disease lies "upstream", yet the clinical phenotype of the disorders differ, although with considerable overlap. Why there should be this distinction is uncertain, but there may be a differential effect on tissues depending on the proportions of product accumulation (phytanic and pristanic acid and bile acid intermediates), or loss of lipid functions "downstream".

In humans, the only peroxisomal disorders of β-oxidation so far identified are those relating to VLCFAs, DHCA/THCA, and pristanic acid. Multiple enzymes are involved (fig 1) and abnormalities of pristanic acid metabolism were first associated with generalised peroxisomal disorders.

This currently described patient showed highly increased pristanic acid concentrations and mildly raised phytanic acid and VLCFA concentrations. Had the pristanic acid concentrations and mildly raised phytanic acid not been measured, the condition would have been missed, as peroxisomal disorders have always been assumed to cause abnormalities of VLCFA or phytanic acid.

The biochemical defect in this case has only recently been characterised as an absence of the α-methylacyl-CoA racemase. There is stereoselectivity of the α-methyl branched acyl CoA esters and the bile acid intermediates, and these must be converted to their S forms before degradation by peroxisomal β-oxidation. Absence of the racemase has the same consequences as a deficiency of the branched chain acyl-CoA oxidase, although in the second R and S stereoisomers accumulate, and in racemase deficiency only R isomers accumulate. Analysis of both enzymes is required to establish the precise defect.

He therefore has a unique combination of features, distinct from the other peroxisomal disorders, but with many features in common, particularly with Refsum's disease. His disease course has been relatively benign.
J Allan, Department of Clinical Biochemistry, Southmead Hospital, Bristol BS10 5NB, UK
S Ferdinandusse, RJA Wanders, Laboratory of Genetic Metabolic Diseases, Emma Children’s Hospital AMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
Correspondence to: Dr B N McLean, Department of Neurology, Royal Cornwall Hospital, Treliske, Truro, Cornwall TR1 3JU, UK
Received 12 September 2000
In revised form 26 September 2001
Accepted 23 October 2001

REFERENCES